Pharming Group delivered strong financial results in Q4 2024 and provided an optimistic 2025 revenue guidance of $315 million to $335 million, driven by the continued success of RUCONEST and Joenja.

Across the recent three months, 4 analysts have shared their insights on Pharming PHAR, expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their recent ...

Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of ...

Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong ...